Sanctuary Advisors LLC Sells 40,570 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)

Sanctuary Advisors LLC lessened its position in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK) by 57.9% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 29,451 shares of the company’s stock after selling 40,570 shares during the period. Sanctuary Advisors LLC’s holdings in Takeda Pharmaceutical were worth $403,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of TAK. Allspring Global Investments Holdings LLC increased its stake in Takeda Pharmaceutical by 62.8% in the third quarter. Allspring Global Investments Holdings LLC now owns 17,759 shares of the company’s stock valued at $253,000 after purchasing an additional 6,852 shares in the last quarter. US Bancorp DE increased its stake in Takeda Pharmaceutical by 11.9% in the third quarter. US Bancorp DE now owns 102,588 shares of the company’s stock valued at $1,459,000 after purchasing an additional 10,925 shares in the last quarter. Van ECK Associates Corp increased its stake in Takeda Pharmaceutical by 6.6% in the third quarter. Van ECK Associates Corp now owns 2,175,236 shares of the company’s stock valued at $30,149,000 after purchasing an additional 134,407 shares in the last quarter. BSW Wealth Partners increased its stake in Takeda Pharmaceutical by 15.7% in the third quarter. BSW Wealth Partners now owns 22,090 shares of the company’s stock valued at $314,000 after purchasing an additional 2,992 shares in the last quarter. Finally, QRG Capital Management Inc. increased its stake in Takeda Pharmaceutical by 4.5% in the third quarter. QRG Capital Management Inc. now owns 282,154 shares of the company’s stock valued at $4,012,000 after purchasing an additional 12,035 shares in the last quarter. Institutional investors own 9.17% of the company’s stock.

Takeda Pharmaceutical Trading Up 3.0 %

TAK opened at $14.84 on Tuesday. Takeda Pharmaceutical Company Limited has a 1-year low of $12.57 and a 1-year high of $15.08. The company has a current ratio of 1.31, a quick ratio of 0.72 and a debt-to-equity ratio of 0.63. The company has a market cap of $47.22 billion, a P/E ratio of 37.10, a price-to-earnings-growth ratio of 0.24 and a beta of 0.51. The company has a fifty day moving average price of $13.44 and a two-hundred day moving average price of $13.89.

Takeda Pharmaceutical (NYSE:TAK) last issued its quarterly earnings data on Thursday, January 30th. The company reported $0.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.34 by $0.08. Takeda Pharmaceutical had a net margin of 4.53% and a return on equity of 9.39%. Analysts predict that Takeda Pharmaceutical Company Limited will post 1.64 EPS for the current fiscal year.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.